BioRestorative Therapies Inc. (NASDAQ:BRTX) revealed on Wednesday new preliminary 26 to 52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 trial of BRTX-100. BRTX-100 is a novel cell-based therapeutic engineered to target body areas with little blood flow. A Phase 2 study is evaluating the safety and efficacy of BRTX-100 in treating cLDD. Up to 99 eligible subjects will be enrolled. The 10 safety run-in subjects reported no serious adverse events (SAEs). There was also no dose (40X106 cells) limiting toxicity at 26 to 52 week…